Equita downgrades Coloplast to 'hold' citing disappointing results

Coloplast A/S

10/02/2026 11:29

** Equita downgrades Danish medical device maker Coloplast COLOb.CO to "hold", citing a pile-up of "disappointing" results and the loss of its high-growth status

** The downgrade follows a significant negative surprise from company's Kerecis wound care unit, which reported just 10% growth against a previously guided 25%

** The brokerage notes negative "one-offs" keep piling up, including US distribution disruptions, product recalls, and extraordinary taxation

** Future risks are also on the horizon, including potential US regulatory changes and the activation of the Center for Medicare and Medicaid Services' (CMS) competitive bidding program

** Out of the 23 analysts covering the stock, four rate it "strong buy"/"buy", 17 "hold", two "sell" - LSEG data

 (Reporting by Vera Dvorakova)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))